These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 25257311)
41. Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2. Zhang S; Chen Q; Liu Q; Li Y; Sun X; Hong L; Ji S; Liu C; Geng J; Zhang W; Lu Z; Yin ZY; Zeng Y; Lin KH; Wu Q; Li Q; Nakayama K; Nakayama KI; Deng X; Johnson RL; Zhu L; Gao D; Chen L; Zhou D Cancer Cell; 2017 May; 31(5):669-684.e7. PubMed ID: 28486106 [TBL] [Abstract][Full Text] [Related]
42. The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients' Survival. Godlewski J; Kiezun J; Krazinski BE; Kozielec Z; Wierzbicki PM; Kmiec Z Biomed Res Int; 2018; 2018():2653623. PubMed ID: 29850494 [TBL] [Abstract][Full Text] [Related]
43. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Jeong W; Kim SB; Sohn BH; Park YY; Park ES; Kim SC; Kim SS; Johnson RL; Birrer M; Bowtell DSL; Mills GB; Sood A; Lee JS Anticancer Res; 2014 Feb; 34(2):811-817. PubMed ID: 24511017 [TBL] [Abstract][Full Text] [Related]
45. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. Santinon G; Pocaterra A; Dupont S Trends Cell Biol; 2016 Apr; 26(4):289-299. PubMed ID: 26750334 [TBL] [Abstract][Full Text] [Related]
46. Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M Mol Reprod Dev; 1995 Dec; 42(4):493-9. PubMed ID: 8607981 [TBL] [Abstract][Full Text] [Related]
47. TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. Chai J; Xu S; Guo F Biochem Biophys Res Commun; 2017 Jun; 488(2):297-302. PubMed ID: 28483529 [TBL] [Abstract][Full Text] [Related]
48. Energy crisis and the Hippo pathway. Wang W; Li X; Chen J Cell Cycle; 2015; 14(13):1995-6. PubMed ID: 25942485 [No Abstract] [Full Text] [Related]
49. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915 [TBL] [Abstract][Full Text] [Related]
50. STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Kim JW; Berrios C; Kim M; Schade AE; Adelmant G; Yeerna H; Damato E; Iniguez AB; Florens L; Washburn MP; Stegmaier K; Gray NS; Tamayo P; Gjoerup O; Marto JA; DeCaprio J; Hahn WC Elife; 2020 Jan; 9():. PubMed ID: 31913126 [TBL] [Abstract][Full Text] [Related]
51. Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. Poma AM; Torregrossa L; Bruno R; Basolo F; Fontanini G Sci Rep; 2018 Jul; 8(1):10623. PubMed ID: 30006603 [TBL] [Abstract][Full Text] [Related]
52. The kelch proteins Gpb1 and Gpb2 inhibit Ras activity via association with the yeast RasGAP neurofibromin homologs Ira1 and Ira2. Harashima T; Anderson S; Yates JR; Heitman J Mol Cell; 2006 Jun; 22(6):819-830. PubMed ID: 16793550 [TBL] [Abstract][Full Text] [Related]
53. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Martin D; Degese MS; Vitale-Cross L; Iglesias-Bartolome R; Valera JLC; Wang Z; Feng X; Yeerna H; Vadmal V; Moroishi T; Thorne RF; Zaida M; Siegele B; Cheong SC; Molinolo AA; Samuels Y; Tamayo P; Guan KL; Lippman SM; Lyons JG; Gutkind JS Nat Commun; 2018 Jul; 9(1):2372. PubMed ID: 29985391 [TBL] [Abstract][Full Text] [Related]